GlassScriptPhysician profile
Cody Mccoy
NPI 1033612841
$17,911.61
in general payments reported to CMS, 2019-2025
21 companies · $7,800 in 2025
The $7,800 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $138 · 2023: $4,908 · 2024: $5,066 · 2025: $7,800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,145 · Food and Beverage: $7,083 · Grant: $2,000 · Education: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,145.28 |
| Food and Beverage | $7,083.41 |
| Grant | $2,000.00 |
| Education | $544.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $6,942.84 | 2023-2025 | Acticor 7 Vr-T Dx, Edora 8 Dr-T, Sentus |
| Boston Scientific Corporation | $4,234.25 | 2023-2025 | Farapulse, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Medtronic, INC. | $3,035.32 | 2024-2025 | Micra, Cobalt Dr Mri Surescan, Onyx Frontier |
| Medical Device Business Services, INC. | $1,523.26 | 2023-2024 | Carto 3 |
| Abbott Laboratories | $511.37 | 2025 | Ensite, Aveir, Perclose Prostyle |
| Cardiva Medical, INC. | $436.27 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 5f Vcs, Ensoetm |
| Biosense Webster, INC. | $404.33 | 2022-2025 | Carto 3, Qdot Micro Catheter, Soundstar |
| Janssen Pharmaceuticals, INC | $172.60 | 2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $120.78 | 2022-2023 | Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.02 | 2023-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.23 | 2024-2025 | Lifevest |
| Abiomed | $65.15 | 2024-2025 | Impella |
| Pfizer INC. | $64.34 | 2024-2025 | |
| Novo Nordisk INC | $47.50 | 2023-2024 | Ozempic |
| Stryker Corporation | $42.85 | 2025 | Target |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $35.63 | 2024 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $28.58 | 2025 | Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $18.03 | 2024 | Arcalyst |
| Amgen INC. | $17.91 | 2023 | Repatha |
| Zoll Circulation INC | $17.89 | 2025 | Therox Ds2 Console, Downstream Cartridge, Catheter |
| Convatec INC. | $16.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Mccoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.